Clinical significance of morphologic characteristics in triple negative breast cancer

Dong Won Ryu, Min Jung Jung¹, Woo Sik Choi, Chung Han Lee

Departments of Surgery and ¹Pathology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

Purpose: No clinically useful target molecule has been identified for triple-negative (TN) breast cancer, i.e., estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor-2-negative phenotype, and its prognosis is poor. The aim of this study is to clarify the clinical and pathologic characteristics of triple negative breast cancer (TNBC). Methods: The study subjects, 87 women with TNBC, were a subset of patients operated at Kosin University Gospel Hospital from January 2000 to December 2005. We examined pathologic characteristics such as tumor necrosis, infiltrating border, lymphocytic infiltration, prominent nucleoli in TNBC. And we studied the correlation between TNBC and several factors related to pathologic morphology. Chi-squared tests were used for statistical analysis. Kaplan-Meier estimates are presented for the survival function, and differences in survival were analyzed using the log rank test. Results: Tumor necrosis was found in 51 patients (58.3%) in TNBC. And infiltrating border was found in 71 patients (81.0%). Also continuous lymphocytic distribution and prominent nucleoli was found in 31 patients (35.7%), 52 patients (59.7%), respectively. No association was detected between pathologic characteristics and other biological markers. Patients with tumor necrosis positive for TNBC didn’t show shorter disease-free survival ($P = 0.4490$) or overall survival ($P = 0.979$) than patients without tumor necrosis. Conclusion: These findings suggest that pathologic characteristics cannot be used to classify triple-negative breast cancer into only two subtypes with differing prognoses. But because our study is small size study, more abundant patients’ dates will be needed to evaluate the morphologic characteristics’ predictive role.

Key Words: Triple negative breast cancer, Tumor necrosis, Lymphocytic infiltration, Prominent nucleoli

INTRODUCTION

By using DNA microarray techniques, it has been shown that breast cancers can be classified into biologically distinct groups based on their gene expression profiles. These groups comprise luminal A (estrogen receptor [ER]-positive and human epidermal growth factor receptor-2 [HER2]-negative), luminal B (ER- and HER2-positive), HER2 (ER-negative and HER2-positive), and triple negative (ER- and HER2-negative) subtypes [1,2]. The TNBC is a heterogeneous group and is further categorized into the basal-like and the normal breast subtypes, which are positive and negative, respectively, for myoepithelial/basal markers such as basal cytokeratins (CKs) (i.e., CK5/6, CK14, and CK17), a-smooth muscle actin, and epidermal growth factor receptor (EGFR) [3,4]. Although
TNBCs account for only 10 to 17% of all breast carcinomas, this subgroup is regarded as important clinically because of the aggressive clinical behavior, poorer patient prognosis, and lack of an established therapeutic target [5,6]. The ratio of basal-like subtype in TNBC was estimated to be up to 56 to 84%. Therefore, characteristic histopathological features of TNBCs are similar with those of the basal-like subtype [7,8]. Characteristic histopathological types that constitute TNBCs and basal-like subtype are high-grade invasive ductal carcinoma of no special type, typical medullary carcinoma, metaplastic carcinomas, and adenoid cystic carcinoma [1,9]. So we present data of histological features of TNBCs and discuss about its morphological spectrum in our hospital case.

**METHODS**

Patients and tissue samples

Tissue samples were obtained from 618 patients with invasive breast cancer who were diagnosed from 2000 to 2005 at Kosin University Gospel Hospital in Busan, Korea. A total of 618 specimens of primary invasive carcinoma were obtained from resected tumor. None of these cancer patients received treatment prior to surgery. The patients underwent standard and partial mastectomies with fully resected axillary dissections. Patients received anthracycline-containing chemotherapy if the tumor was node positive. Endocrine therapy was given for 5 years to patients with ER-positive tumors. Median follow-up was 5.5 years (range, 0.3 to 14.8 years), during which there were 84 relapses and 32 deaths.

**Immunohistochemical techniques**

The expression of ER, progesterone receptor, HER2, CK5/6 and other biological markers was determined immunohistochemically in paraffin-embedded tissue specimens. Table 1 summarizes all the antibodies, dilutions, incubation times, and cutoff values used for this analysis. All data were collected from the pathology reports. Histopathological features such as hormone receptor status and HER2/neu status on immunohistochemistry (Dako, Copenhagen, Denmark) were all analyzed at the Institute of Pathology at the Kosin University Gospel Hospital. Expressions of p53, ERa, Ki-67, and ErbB2 were determined immunohistochemically on paraffin sections using antibodies against ERa (Dako), Ki67 (Dako), ErbB2 (Dako), p53 (Dako). Tumor necrosis was defined as the presence of necrosis of any dimension in a section of invasive cancer. Histologic grading was performed using the criteria of Bloom and Richardson. Lymphatic vascular invasion was defined as the presence of tumor emboli in peritumoral lymphatic spaces, capillaries or postcapillary venules. ER status and progesterone receptor status were taken as positive if more than 10% of tumor cells showed staining. Immunohistochemical score of 3+ or fluorescence in situ hybridization+ for HER2 was accepted as HER2 positivity.

**Statistical analysis**

Statistical tests were performed using the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). The survival function was calculated from the time of the pathologic diagnosis to the occurrence of death. Survival data were censored on December 31, 2009, which was the date on which the sur-

---

Table 1. Antibodies, dilutions, incubation times, and cutoff values

| Marker | Species         | Manufacturer | Dilution | Incubation time | Cutoff value |
|--------|----------------|--------------|----------|-----------------|--------------|
| ER     | Mouse mAb      | Dako         | 1 : 50   | 60 min, RT     | ≥10%         |
| PgR    | Mouse mAb      | Dako         | 1 : 100  | 60 min, RT     | ≥10%         |
| HER2   | Rabbit poly    | Dako         | 1 : 250  | 60 min, RT     | 3+ or FISH+  |
| Ki-67  | Mouse mAb      | Dako         | 1 : 50   | 60 min, RT     | ≥20%         |
| p53    | Mouse mAb      | Dako         | 1 : 50   | 60 min, RT     | ≥10%         |
| CK5/6  | Mouse mAb      | Dako         | 1 : 100  | 60 min, RT     | ≥5%          |

ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor-2; RT, room temperature; FISH, fluorescence in situ hybridization.
vival data were correlated with the death registry for the last time or 5 years after the onset of the disease. Kaplan-Meier estimates are presented for the survival function, and differences in survival were analyzed using the log rank test. Associations between specific histopathological and clinical survival estimates and curves were established using the Kaplan-Meier method and differences in observed survival distribution among patient subgroups were tested with two-sided log-rank test. All survival rates were presented with their standard errors. We used Pearson’s correlation to determine the association of pairs of explanatory variables and differences in qualitative variables were evaluated by chi-squared test, where necessary. All P-values were two-sided and a P-value of less than 0.05 was considered to indicate a statistically significant difference.

**RESULTS**

The main clinicopathological characteristics of the patients in our series are summarized in Table 2. Mean age was 54 years. Luminal A was reported in 166 patients (26.9%). Luminal B, HER2 and triple negative type was reported in 178 patients (28.9%), 162 patients (26.3%), 111 patients (17.9%), respectively. Among the 111 TNBC patients, twenty four had missing data as a result of a complete table.
puter failure, so that 87 TNBC patients are included in the final morphologic characteristics data set. Other reasons for ineligibility included incompetent specimen. Tumor necrosis was found in 51 patients (58.3%) in TNBC. And infiltrating border was found in 71 patients (81.0%). Also continuous lymphocytic distribution and prominent nucleoli was found in 31 patients (35.7%), 52 patients (59.7%), respectively. No association was detected between pathologic characteristics and other biological markers (Table 3). Among TNBC patients, 87 patients could be studied about CK5/6. According to the positivity of CK5/6, 24 of

| Table 4. Cytological findings of triple negative breast tumor characteristics and association with CK5/6 positivity |
|---------------------------------------------------------------|
| **Characteristics**         | **CK5/6 negative** | **CK5/6 positive** | **Total** | **P-value** |
|-----------------------------|--------------------|--------------------|-----------|-------------|
| Necrosis                    |                    |                    |           | 0.202       |
| Yes                         | 35 (54.8)          | 16 (66.6)          | 51 (58.3) |             |
| No                          | 28 (45.2)          | 8 (33.3)           | 36 (41.7) |             |
| Border                      |                    |                    |           | 0.947       |
| Pushing                     | 4 (6.5)            | 1 (4.2)            | 5 (6.0)   |             |
| Borderline                  | 8 (12.9)           | 3 (12.5)           | 11 (13.0) |             |
| Infiltrating                | 51 (80.6)          | 20 (83.3)          | 71 (81.0) |             |
| Lymphocyte                  |                    |                    |           | 0.360       |
| Cuffing                     | 3 (4.8)            | 0 (0)              | 3 (3.6)   |             |
| Continuous                  | 20 (32.3)          | 11 (45.8)          | 31 (35.7) |             |
| No                          | 40 (62.9)          | 13 (54.2)          | 53 (60.7) |             |
| Nucleoli                    |                    |                    |           | 0.348       |
| Prominent                   | 34 (54.7)          | 18 (75.0)          | 52 (59.7) |             |
| Moderate                    | 29 (45.3)          | 6 (25.0)           | 35 (40.3) |             |

Values are presented as no. of patients (%).

| Fig. 1. Kaplan-Meier estimates for disease-free survival according to tumor necrosis. |
|--------------------------------------------------------------------------------------------|

| Table 5. Five years overall and disease-free survival probabilities in triple negative breast cancer as calculated by Cox proportional hazards regression model (P-value for log rank test) |
|------------------------------------------------------------------------------------------------|
| **DFS**                          | **OS**                         |
|----------------------------------|--------------------------------|
| ****HR**                          | **95% CI**                      | **P-value**                         | **HR**                          | **95% CI**                      | **P-value**                         |
|-----------------------------------|--------------------------------|-------------------------------------|---------------------------------|---------------------------------|-------------------------------------|
| pT                                | 3.476                          | 1.390-8.693                        | 0.006                           | 5.956                          | 1.317-26.92                        | 0.020                              |
| pN                                | 1.690                          | 1.144-2.495                        | 0.008                           | 2.496                          | 1.142-5.454                        | 0.022                              |
| AJCC stage                        | 1.060                          | 1.011-1.111                        | 0.016                           | 1.119                          | 0.970-1.293                        | 0.124                              |
| GRADE                             | 0.678                          | 0.349-1.699                        | 0.183                           | 0.830                          | 0.467-2.897                        | 0.1167                             |
| p53                               | 0.750                          | 0.270-2.083                        | 0.582                           | 0.564                          | 0.562-2.678                        | 0.6217                             |
| Ki-6                              | 1.564                          | 0.679-2.347                        | 0.054                           | 0.863                          | 0.435-2.967                        | 0.1259                             |
| CK5/6                             | 0.371                          | 0.047-2.922                        | 0.325                           | 0.786                          | 0.327-6.579                        | 0.2752                             |
| Necrosis                          | 1.548                          | 0.499-4.802                        | 0.449                           | 1.024                          | 0.171-6.133                        | 0.979                              |
| Lymphocyte infiltration           | 2.038                          | 0.287-7.075                        | 0.262                           | 1.567                          | 0.354-6.786                        | 0.543                              |
| Prominent nucleoli               | 0.553                          | 0.214-1.429                        | 0.2210                          | 1.053                          | 0.309-3.592                        | 0.934                              |

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.
a median follow-up of 5.5 years, 84 patients (13.6%) had a recurrence. And 32 patients (5.2%) had a death. Among TNBC, we observed 11 relapses in 63 patients (17.5%) with CK5/6 (−) TNBC and only 1 relapse in 24 patients (4.1%) with CK5/6 (+) TNBC. Disease-free survivals was not shorter in patients with CK5/6 (+) TNBC at diagnosis when compared with patients with CK5/6 (−) TNBC (hazard ratio [HR], 0.371; 95% confidence interval [CI], 0.047 to 2.922; P = 0.3257). Also overall survival was not shorter in patients with CK5/6 (+) TNBC (HR, 0.786; 95% CI, 0.327 to 6.879; P = 0.2752) (Table 5).

DISCUSSION

Among the high-grade invasive ductal carcinomas, a large part of cases is made up of high-grade solid-tubular carcinoma (also called as atypical medullary carcinoma) [1,10]. Typical medullary carcinoma is defined as a well-circumscribed carcinoma composed of poorly differentiated cells arranged in large sheets syncytial architecture with scant stroma, with no glandular structures, and with a prominent lymphoplasmacytic infiltration, and with a pushing border of invasion [11,12]. Central geographic or comedo-type necrosis may also be seen. Tumors showing the association of a predominantly syncytial architecture with only two or three of the other above-mentioned criteria are designated as atypical medullary carcinoma [13,14]. High-grade invasive ductal carcinoma with a large central acellular zone is also found relatively frequently in TNBCs. The independent prognostic significance of tumor necrosis has been studied extensively [15,16]. Controversy exists about the definition and classification of necrosis, with respect to the amount of necrosis that is considered to be significant as well as the relative distribution of necrosis within intraductal and invasive components of a tumor [17,18]. There is evidence indicating that the prognostic significance of tumor necrosis is time dependent. For example, Gilchrist et al. found that tumor necrosis defined as the “presence of confluent necrosis of any dimension in a section of invasive cancer that could be distinguished at intermediate magnification,” was a significant predictor of time to recurrence and overall survival with 10-year follow-up [19,20]. And previous data add further support to the perception that extensive necrosis is a prognostically unfavorable feature in invasive mammary carcinoma, possibly reflecting a growth rate so rapid that it exceeds tumor sustaining angiogenesis to a substantial degree [21,22]. And the prognostic significance of stromal inflammatory cells within and around invasive duct carcinomas has been the subject of considerable interest and some controversy [23,24]. The reaction consists mainly of mature lymphocytes with a variable admixture of plasma cell, histiocytes, neutrophils, and mast cells. Rarely, plasma cells or eosinophils predominate. Tumors with plasma cell predominance are usually medullary carcinomas or carcinomas with medullary features [15,16]. The marked lymphoplasmacytic reaction observed in medullary carcinoma also occurs in a minority of non medullary invasive duct carcinomas [17,18].

In conclusion, these findings suggest that morphologic characteristics cannot be used to classify TNBC into at least two subtypes with differing prognoses. One of the reasons is that only a small number of patients were examined in this study, making it difficult to reach statistical significance. More abundant patients’ data will be needed to evaluate the morphologic characteristics’ predictive role.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This article was granted by Kosin Medical college 2008 and we would like to acknowledge Junyeop Daniel Roh and Youktun Sophie Roh for their contributions in collecting and organizing the included data, as well as in aiding translations.
REFERENCES

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-501.
4. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
5. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-104.
6. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
7. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
9. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
10. Rakha EA, Putti TC, Abd El-Rehim DM, Paiash C, Green AR, Powe DG, et al. Morphological and immunohistochemical analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
11. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
12. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
13. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
14. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.
15. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
16. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007;16 Suppl 2:S72-7.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
18. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999;30:1134-9.
19. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
20. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-8.
21. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000;37:175-81.
22. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
23. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, Sarrió D, Martin-Guijarro Mdel C, Hernandez L, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 2007;31:501-8.
24. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008;61:615-20.